MedTech Dive April 4, 2024
Elise Reuter

The CEO of Prenosis told MedTech Dive the company sees third-party validation as important, with the FDA having clarified that certain decision support tools should be regulated as medical devices.

Dive Brief:

  • The Food and Drug Administration granted de novo clearance to an AI tool to help clinicians predict and diagnose sepsis, the first time the agency has authorized such a tool.
  • The Sepsis Immunoscore software, developed by Chicago-based Prenosis, provides a risk score for clinicians on a patient having or developing sepsis within 24 hours. The score is based on 22 parameters, including respiratory rate, blood pressure and white blood cell count.
  • Hospitals already use early sepsis detection tools, despite lacking FDA review. The agency clarified in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Health System / Hospital, Medical Devices, Provider, Technology
Related Articles:
The Time Is Now For Federal Reform Of Direct-To-Consumer Advertising Of Prescription Drugs
Regulatory tracker: FDA offers Pfizer's Tivdak full nod in cervical cancer
Next-generation psychedelic workers
Pfizer cervical cancer drug gets full approval
FDA defends lab test rule, as critics fear industry upheaval

Share This Article